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In this article, we will attempt to present and delineate the pros
and cons of performing stereotactic radiosurgery (SRS) to the
surgical cavity after resection of a single brain metastasis. In
this regard, one must consider the relative merits of SRS
vis-a`-vis whole brain radiotherapy (WBRT) in the context of
local control at the resection cavity, distant failure, overall sur-
vival, the ability to preserve neurocognition and associated
quality of life, treatment toxicity, and ease of integration with
systemic therapy.
Historical Perspective
The role of WBRT, long the mainstay in the management of
brain metastases, is evolving. In 1990, the landmark random-
ized brain metastasis trial published by Patchell and col-
leagues1 established surgical resection followed by WBRT as
the standard of care for the management of a single brain me-
tastasis, as there was a survival benefit associated with the sur-
gical resection of a single brain metastasis. The Radiation
Therapy Oncology Group (RTOG) 95-08 trial established a
survival benefit for the addition of SRS to WBRT for single
brain metastases.2 The publication of these 2 trials, and sup-
porting studies, led to worldwide adoption of radiosurgery
and surgery in combination with WBRT for the initial manage-
ment of limited brain metastases over the next 2 decades. Four
randomized trials looking at SRS and the value of adding or
omitting WBRT3 –6 have now been completed. The results
from these 4 trials have questioned the need for routine
WBRT following SRS, while favoring SRS alone in the manage-
ment of 1 to 3 brainmetastases. Ameta-analysis7 of the 3 pub-
lished randomized trials (the Japanese Radiation Oncology
Study Group, MD Anderson Cancer Center [MDACC], European
Organisation for Research and Treatment of Cancer [EORTC])
has also reported a survival benefit associated with patients
randomly assigned to SRS alone who were younger than 50
years of age, further questioning the role of WBRT.
Performing surgery alone for a single brain metastasis is not
supported by randomized data. A second randomized trial,
published in 1998, by Patchell and colleagues,8 of resection
alone of a brain metastasis compared with resection followed
by WBRT, showed a local failure rate at the resection cavity
of 46% with surgery alone and 10% with surgery and WBRT
(P, .001). The EORTC 22952-26001 trial was unique in that it
included patients after either surgery or radiosurgery who were
randomized to WBRTor observation. This trial confirmed the in-
sufficiency of surgical resection alone for brain metastasis,
demonstrating a recurrence rate in the surgical cavity of
60% without adjuvant radiation. Concerns raised by random-
ized studies on the neurocognitive sequelae associated with
postoperative WBRT, and the infeasibility of omitting all adju-
vant radiation, led some institutions to replace postoperative
WBRT with postoperative SRS, a practice trend that is
increasing.
Postoperative Stereotactic Radiosurgery: Pros
Local Control and Overall Survival
A review of single institutional retrospective studies supports
postoperative radiosurgery to the surgical cavity of resected
brain metastasis with local control rates of 85%–100%.9 The
median survival for selected published studies is 14.2 months
(range, 10–20.5 mo). Our own published institutional experi-
ence at the University of Southern California reported on 82
patients undergoing resection of a brain metastasis and subse-
quent radiosurgery to the cavity. The actuarial rate of local fail-
ure in the cavity was 13% at 12 months. The median overall
survival in our series was 20 months.10 These studies are limit-
ed by their retrospective nature, but a recently published phase
II trial by Brennan et al11 investigating SRS boost after surgery
demonstrated a local control rate of 78% at 12months. Impor-
tantly, 10 of the 50 patients enrolled did not receive the
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planned boost, due to progression, large cavity size, or other
medical reasons, which demonstrates the bias inherent in
retrospective analyses.
Overall, the reported local control rates and survival follow-
ing SRS to the surgical cavity are comparable to those obtained
with WBRT, suggesting that postoperative SRS is as effective as
WBRT.
Neurocognitive Outcomes
Extrapolation from 2 randomized trials conducted by MDACC
and the North Central Cancer Treatment Group (NCCTG)
would strongly suggest that replacing postoperative WBRT
with SRS would lead to improved neurocognitive outcomes.
From the MDACC trial, which enrolled patients with 1–3 intact
brain metastases and randomly assigned them to observation
or WBRT, one can estimate that for resected brain metastases,
postoperative SRS would be estimated to have a similar 25%
decline on the Hopkins Verbal Learning Test (HVLT), while post-
operative WBRT would be estimated to have a similar 50%
decline on the HVLT at 4 months. The NCCTG N0574 (Alliance)
trial for patients with 1 to 3 intact brain metastases reported
decline in cognitive function at 3 months measured by the
HVLT Delayed Recall Test more frequently with the addition of
WBRT (51.1%) compared with SRS alone (19.7%). Additional
evidence for the deleterious effect of WBRT on cognitive func-
tion comes from RTOG 0214,12 which randomized non-small
cell lung cancer patients without evidence of brain disease to
prophylactic cranial irradiation or observation. Decrements in
HVLT scores were seen persisting up to 1 year post WBRT. As
systemic therapies improve, patients with metastatic disease,
even within the CNS, will live longer, and the importance of
preservation of cognitive function will increase, suggesting
that WBRT should be delayed as long as possible. The ongoing
NCCTG N107C trial, which randomizes patients to postoperative
SRS or postoperative WBRT, has the primary goal and hypothe-
sis of determining if there is less incidence of neurocognitive
progression measured at 6 months postradiation in patients
randomized to postoperative SRS compared with postoperative
WBRT. This should provide much needed neurocognitive out-
come data in the context of the postoperative setting. WBRT
with hippocampal sparing has been proposed as a means by
which the cognitive decline of patients receiving WBRT may
be reduced, but prospective clinical data are still forthcoming.13
SRS cavity boost offers another way to reduce cognitive deficits
in patients receiving radiotherapy to the brain.
Toxicity of Treatments
WBRT can cause fatigue, alopecia, skin erythema, dermatitis,
folliculitis, otitis media, taste alteration, and appetite changes.
SRS is typically not associated with the aforementioned acute
toxicities, and the vast majority of SRS patients do not experi-
ence any acute toxicity. Rarely, SRS patients may experience
headaches, seizures, edema, or hemorrhage.
The most serious and concerning potential late toxicity as-
sociated with WBRT is neurocognitive decline. WBRT may also
be associated with a risk of leukoencephalopathy, especially
when there is a close temporal relationship with chemotherapy.
Moreover, patients receiving WBRTcan develop dementia when
large radiation fractions (.3 Gy) are used.14 SRS is associated
with improved preservation of neurocognitive function over
WBRT but may cause long-term treatment-related imaging
changes on MRI around the surgical cavity, which may develop
into radiation necrosis. The reported rate of pathologically prov-
en radionecrosis in the previously mentioned prospective trial
by Brennan et al was 17.5%.11
Logistics and Coordination of Care
Postoperative SRS is advantageous to both patient and caregiv-
er, because it can be delivered within a day or 2 following sur-
gery and completed in 1 day. Postoperative WBRT cannot be
initiated for at least 10 days to allow for adequate wound heal-
ing, and usually requires 2 weeks to complete. If patients are
receiving systemic therapy, a break from chemotherapy is nec-
essary during WBRT administration, and up to 1 month follow-
ing its completion. With postoperative SRS there is minimal to
no interruption of systemic agents. As a result, concerns re-
garding controlling systemic disease and avoiding systemic
tumor progression while patients undergo CNS treatment are
minimized when postoperative SRS is chosen over WBRT. One
of the major difficulties with postoperative SRS is proper delin-
eation of the cavity and addition of an appropriate margin.
Early experiences reported that rates of local failure correlated
with increasing conformality of the treatment plan and subse-
quently found that at least a 2-mm margin around the cavity
should be treated to avoid excess failure.15 There is a high de-
gree of variation in size and shape of postoperative cavities,
which can make accurate contouring difficult, something that
is less than desirable for such a precise treatment. Preoperative
SRS is one potential way to mitigate this concern.16
Quality of Life
The EORTC study evaluated health-related quality of life
(HRQoL) as a secondary endpoint, considering global health
status; physical, cognitive, role, and emotional functioning;
and fatigue.17 Patients reported better HRQoL in the observa-
tion arm than in the WBRTarm, with differences that were stat-
istically significant at 9 months in global health status, at 8
weeks in physical functioning, at 12 months in cognitive func-
tioning, and at 8 weeks in fatigue. The study did not find obser-
vation with serial MRI to be detrimental to HRQoL.
Conclusions
Evidence from 4 randomized radiosurgical trials and multiple
institutional retrospective studies strongly support SRS alone
for a limited number of newly diagnosed brain metastases
based on: local tumor control, overall survival, neurocognitive
preservation, and HRQoL, as well as acute and long-term toxic-
ity profiles. Here we have shown that postoperative SRS pro-
vides similar control rates to WBRT, with potentially less
neurocognitive toxicity. The ongoing N107C trial should provide
level I evidence that will further clarify the risk-benefit analysis
between administering postoperative WBRT versus SRS. Other
means to improve outcomes, such as hippocampal-sparing
WBRTand preoperative SRS, are promising andmay be evaluat-
ed in future trials.
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When addressing the cons of SRS to the surgical cavity in single
brain metastasis, one must take into account 3 points: the ex-
istence of several unsolved technical and clinical problems, the
risk of radionecrosis and other neurological complications, and
the risk of leptomeningeal relapse.
Unsolved Problems
Despite a growing body of literature,18–22 SRS to the resection
cavity is not superior toWBRT in terms of local or distant control
at 1 and 2 years.
Some technical issues are still matters of debate.11,15,23 The
optimal dose and fractionation, especially for large (.3 cm)
brain metastases, without or with superficial/dural pial involve-
ment that could be at higher risk for local failure, are unknown.
The same holds true for the optimal margin around the resec-
tion cavity to be included in the treatment field. From a clinical
point of view, to date there is lack of information on HRQoL and
neurocognitive functions following SRS to the resection cavity
compared with those following the other therapeutic options
(surgery or SRS alone, surgery or SRS plus WBRT). Moreover, it
is unknown whether postoperative SRS is superior to SRS at
the time of tumor progression after initial observation following
surgery.
Risk of Radionecrosis and Other Neurological
Complications
The risk of radionecrosis following postoperative SRS11,23,24 is
higher (between 5% and 17.5%) than that reported by the
EORTC study5 with WBRT following either surgery or radiosur-
gery (2.6%) and could increase over time (7% at 1 y and 16%
at 2 y).23 However, the actual incidence of pathologically prov-
en radionecrosis is unknown, as often the values reported in the
different series represent a combination of biopsy-proven and
MRI-suspected cases of radionecrosis.
There is lack of information on the clinical counterparts of
radionecrosis and on the incidence of acute complications of
SRS, such as seizures, headache, and hemorrhage.
On the other hand, an increase of T2 signal changes on MRI
around the resection cavity (radiation-related edema?) has
been reported in 10.8% of patients,25 and it would be impor-
tant to know whether these patients concomitantly had neu-
rological symptoms or were asymptomatic.
One of the risks following SRS is the steroid dependency
to control chronic edema: so far, neither frequency nor dura-
tion of steroid use following postoperative SRS has been
recorded.
In case of suspicion of symptomatic radionecrosis, there is
often the need for additional neuroimaging techniques (MR
spectroscopy, MRI perfusion, PET with 2-fluoro-2-deoxy-D-
glucose or amino acids) that often yield conflicting results,
and bevacizumab could be clinically useful26; however, all
these things and possible salvage SRS and other therapies
could lead to an increase of financial costs.
Risk of Leptomeningeal Relapse
The incidence of a leptomeningeal relapse following SRS to the
resection cavity ranges in the different series from 8% to
13%.22,24,27–29 A possible explanation could be that the surgi-
cal spillage is not treated with postoperative SRS, as it is likely
beyond the radiation field, but would be treated with postoper-
ative WBRT.
Patients with breast histology could be at higher risk (at 1 y,
24% vs 9%).29 It is unknown whether the inclusion of WBRT
would decrease this risk of leptomeningeal disease or whether
the biology of brain metastases from breast cancer represents
an intrinsic risk for this complication. To better characterize this
risk, all the future reports on the use of SRS to the resection cav-
ity should include the 3 compartments of failure: local, distant,
and leptomeningeal.
Conclusions
The main limitations of available studies on postoperative SRS
in single brain metastasis include relatively small sample size,
short follow-up, heterogeneous primary histologies, unknown
disease stage, and concurrent use of chemotherapy.
With the lack of clear risk-benefit data and the likelihood of
increased financial costs to patients and to society, it is imper-
ative that SRS to the surgical cavity be studied in multi-
institutional randomized trials before use in routine clinical
practice.30
The ongoing phase III trial of postoperative SRS versus post-
operative WBRT will give a definitive answer. Moreover, hippo-
campal avoidance and preoperative SRS could represent other
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